Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China

References

• Organization WH. (2022). WHO Coronavirus (COVID-19) Dashboard. 2022: https://covid19.who.int/.
   Google Scholar
• Organization WH. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2021: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
   Google Scholar
• Callaway E. Omicron likely to weaken COVID vaccine protection. Nature. 2021;600(7889):367–368.
   PubMed Web of Science ®Google Scholar
• Callaway E, Ledford H. How bad is omicron? what scientists know so far. Nature. 2021;600(7888):197–199. Epub 2021/12/04.
   PubMed Web of Science ®Google Scholar
• Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 omicron has extensive but incomplete escape of pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021 Dec 17. Epub 2021/12/16. PMID: 34909788. doi: 10.1101/2021.12.08.21267417. [Preprint].
   Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV; 2, omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–84 e15.
   PubMed Web of Science ®Google Scholar
• Carreno JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 omicron. Nature. 2022;602(7898):682–688.
   PubMed Web of Science ®Google Scholar
• Muik A, Lui BG, Wallisch AK, et al. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022;375(6581):678–680.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med. 2022;28(5):1063–1071.
   PubMed Web of Science ®Google Scholar
• Syed AM, Ciling A, Taha TY, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc Natl Acad Sci U S A. 2022;119(31):e2200592119, doi:10.1073/pnas.2200592119.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA. 2022;327(7):639–651. doi:10.1001/jama.2022.0470.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID; 19, vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546.
   PubMed Web of Science ®Google Scholar
• Tracker CV. Vaccine candidates in clinical trials. 2022: https://covid19.trackvaccines.org/vaccines/.
   Google Scholar
• China NHCotPsRo. Diagnosis and treatment plan for COVID 19(trial version 9). Clin JC lin Infect Dis. 2022;15(2):81–89. [Chinese].
   Google Scholar
• Stalcrantz J, Kristoffersen AB, Boas H, et al. Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 omicron variant compared with the delta variant in Norway. Scand J Public Health. 2022;50(6):676–682. doi:10.1177/14034948221108548.
   PubMed Web of Science ®Google Scholar
• Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, et al. High rate of asymptomatic carriage associated with variant strain omicron. medRxiv. 2022 Jan 14. Epub 2022/01/20. PMID: 35043118. doi:10.1101/2021.12.20.21268130. [Preprint]
   Google Scholar
• Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared With previous waves. JAMA. 2022;327(6):583–584. doi:10.1001/jama.2021.24868.
   PubMed Web of Science ®Google Scholar
• Organization WH. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection. 7 June 2022:https://www.who.int/publications/i/item/9789240051829.
   Google Scholar
• Mayr FB, Talisa VB, Castro AD, et al. COVID-19 disease severity in US veterans infected during omicron and delta variant predominant periods. Nat Commun. 2022;13(1):3647), doi:10.1038/s41467-022-31402-4.
   PubMed Web of Science ®Google Scholar
• Butt AA, Yan P, Shaikh OS, et al. Rate and risk factors for severe/critical disease Among fully vaccinated persons With breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a high-risk national population. Clin Infect Dis. 2022;75(1):e849–ee56. doi:10.1093/cid/ciab1023.
   PubMedGoogle Scholar
• Wu D, Ye Y, Tang L, et al. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by delta and omicron variants. Emerg Microbes Infect. 2022;11(1):1950–1958.
   PubMed Web of Science ®Google Scholar
• Li M, Liu Q, Wu D, et al. Association of COVID-19 vaccination and clinical severity of patients infected with delta or omicron variants - China, May 21, 2021-February 28, 2022. China CDC Wkly. 2022;4(14):293–297. doi:10.1080/22221751.2022.2103455.
   PubMedGoogle Scholar
• Li Ka Shing Faculty of Medicine TUoHK. HKUMed proposes forward planning after Hong Kong’s fifth wave of Omicron BA.2. 2022-3-26. https://www.med.hku.hk/en/news/press/20220322-updates-on-modelling-the-omicron-fifth-wave.
   Google Scholar
• McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–1443.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kwatra G, Myers JE, et al. Population immunity and COVID-19 severity with omicron variant in South Africa. N Engl J Med. 2022;386(14):1314–1326. doi:10.1056/NEJMoa2119658.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043–2054. doi:10.1001/jama.2021.19499.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N Engl J Med. 2022;386(19):1804–1816. doi:10.1056/NEJMoa2200797.
   PubMed Web of Science ®Google Scholar
• Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron. Cell. 2022;185(5):847–859. e11. doi:10.1016/j.cell.2022.01.015.
   PubMed Web of Science ®Google Scholar
• Wang CY, Hwang KP, Kuo HK, et al. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against delta and omicron variants. J Clin Invest. 2022;132(10.
   Web of Science ®Google Scholar
• GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7(69):eabo2202), doi:10.1126/sciimmunol.abo2202.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022;22(7):959–966. doi:10.1016/S1473-3099(22)00141-4.
   PubMed Web of Science ®Google Scholar
• Petersen MS SIK, Eliasen EH, Larsen S, et al. Clinical characteristics of the omicron variant - results from a nationwide symptoms survey in the Faroe Islands. Int J Infect Dis. 2022;122:636–643. doi:10.1016/j.ijid.2022.07.005.
   PubMed Web of Science ®Google Scholar
• Abu Jabal K, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6).
   PubMedGoogle Scholar
• Notarte KI, Ver AT, Velasco JV, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;59(6):373–390.
   PubMed Web of Science ®Google Scholar
• Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11(1):337–343. doi:10.1080/22221751.2021.2022440.
   PubMed Web of Science ®Google Scholar
• Mok CKP, Chen C, Yiu K, et al. A randomized clinical trial using CoronaVac or BNT162b2 vaccine as a third dose in adults vaccinated with Two doses of CoronaVac. Am J Respir Crit Care Med. 2022;205(7):844–847. doi:10.1164/rccm.202111-2655LE.
   PubMed Web of Science ®Google Scholar
• Lin Z, Wu J, Huang R, et al. Comparison of safety of different vaccine boosters following Two-dose inactivated vaccines: A parallel controlled prospective study. Vaccines (Basel. 2022;10(4). Epub 2022/04/24.
   Web of Science ®Google Scholar